Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05673512

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

To Evaluate IAH0968 in Combination With CAPEOX in a Phase II/III Clinical Study of HER2-positive Metastatic Colorectal Cancer

Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.

Conditions HER2 Gene Mutation

Interventions Injection of IAH0968 + CAPEOX PLACEBO+CAPEOX

Updated 6 times since 2023 Last updated: Feb 18, 2024 Started: May 12, 2023 Primary completion: Mar 1, 2025 Completion: Mar 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05673512, this PHASE2/PHASE3 trial focuses on HER2 Gene Mutation and remains ongoing. Sponsored by SUNHO（China）BioPharmaceutical CO., Ltd., it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Mar 2026 — Present [monthly]

Unknown PHASE2/PHASE3

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3
Aug 2023 — Mar 2024 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2023 — Aug 2023 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SUNHO（China）BioPharmaceutical CO., Ltd.

Data source: SUNHO（China）BioPharmaceutical CO., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenyang, China